Risk Factor C (Monitor therapy)

Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.)

May intensify salicylates' harmful or hazardous effects. Bleeding risk could rise as a result.

Ajmaline

Salicylates may intensify Ajmaline's harmful or toxic effects. In particular, there may be an elevated risk for cholestasis.

Ammonium Chloride

May raise the level of salicylates in the serum.

Angiotensin-Converting Enzyme Inhibitors

Angiotensin-Converting Enzyme Inhibitors' nephrotoxic effects may be made worse by salicylates. The therapeutic benefit of angiotensin-converting enzyme inhibitors may be reduced by salicylates.

Anticoagulants

Salicylates may strengthen the anticoagulant action of clotting factors.

Benzbromarone

Salicylates may diminish the therapeutic effect of Benzbromarone.

Blood Glucose Lowering Agents

Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents.

Calcium Channel Blockers

Magnesium salts' harmful or hazardous effects could be amplified. Calcium Channel Blockers' hypotensive effects may be strengthened by magnesium salts

Corticosteroids (Systemic)

Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.

Loop Diuretics

Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates.

Neuromuscular-Blocking Agents

Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.

Probenecid

Salicylates may reduce Probenecid's therapeutic efficacy.

Salicylates

May enhance the anticoagulant effect of other Salicylates.

Thrombolytic Agents

Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.

Valproate Products

Salicylates may increase the serum concentration of Valproate Products.

Risk Factor D (Consider therapy modification)

Alfacalcidol

May raise the level of magnesium salts in the serum.

Alpha-Lipoic Acid

Alpha-Lipoic Acid may be less readily absorbed when taken with magnesium salts. Magnesium salts may be less readily absorbed when alpha-lipoic acid is present.

Bictegravir

Polyvalent Cation Containing Products may decrease the serum concentration of Bictegravir. Management: Administer bictegravir under fasting conditions at least 2 hours before or 6 hours after polyvalent cation containing products. Coadministration of bictegravir with or 2 hours after most polyvalent cation products is not recommended.

Bisphosphonate Derivatives

Polyvalent Cation Containing Products may decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral medications containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate. Exceptions: Pamidronate; Zoledronic Acid.

Calcitriol (Systemic)

May raise the level of magnesium salts in the serum. Treatment: If a patient is also taking calcitriol, consider using a non-magnesium antacid or phosphate-binding medication. Serum magnesium concentrations should be carefully watched if magnesium-containing products must be used with calcitriol

Carbonic Anhydrase Inhibitors

Salicylates may make Carbonic Anhydrase Inhibitors more harmful or poisonous. This identical combination may increase salicylate toxicity. Management: Whenever you can, stay away from these pairings. Use of dichlorphenamide with aspirin at high doses is not advised. If a different combination is used, patients should be closely watched for side effects. There have been reports of tachypnea, anorexia, lethargy, and coma. Brinzolamide and dorzolamide are exceptions.

Deferiprone

Items containing polyvalent cations may lower the level of deferiprone in the serum. Treatment: Provide deferiprone at least four hours apart from oral drugs or dietary supplements containing polyvalent cations.

Dolutegravir

Magnesium salts may lower the level of dolutegravir in the serum. Treatment: Dolutegravir should be given at least two hours before or six hours after taking oral magnesium salts. While taking oral magnesium salts, provide the dolutegravir/rilpivirine combination product at least 4 hours before or 6 hours after.

Doxercalciferol

Magnesium salts' hypermagnesemic impact might be enhanced. While treating individuals who are also on doxercalciferol, take into account utilising an antacid or phosphate-binding medicine that doesn't contain magnesium. Serum magnesium concentrations should be carefully watched if magnesium-containing products must be taken with doxercalciferol.

Eltrombopag

Products containing polyvalent cations may lower the serum concentration of eltrombopag. Treatment: Provide eltrombopag at least two hours before or four hours after taking any oral medication containing polyvalent cations.

Gabapentin

Gabapentin's CNS depressive effects may be strengthened by magnesium salts. Magnesium sulphate at large doses administered intravenously or epidurally, in particular, may increase the CNS depressive effects of gabapentin. Magnesium salts may lower the level of gabapentin in the blood. Treatment: Provide gabapentin at least two hours after taking an antacid that contains magnesium. Keep a watchful eye on the patients for signs of a diminished response to gabapentin medication. If high dosage IV/epidural magnesium sulphate is given, keep an eye out for CNS depression.

Ginkgo Biloba

May enhance salicylates' anticoagulant effects. Management: Take into account alternatives to this agent combination. If you use salicylates and ginkgo biloba together, keep an eye out for any bleeding symptoms and indications, especially intracranial haemorrhage.

Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry)

May intensify salicylates' harmful or hazardous effects. Bleeding could happen.

Hyaluronidase

Salicylates may reduce Hyaluronidase's ability to treat disease. Treatment: Standard doses of hyaluronidase may not produce the desired clinical response in patients receiving salicylates (especially at higher doses). Hyaluronidase may be needed at higher doses.

Levothyroxine

Magnesium salts may lower the level of levothyroxine in the blood. Treatment: Provide oral magnesium salts at least 4 hours apart from oral levothyroxine.

Methotrexate

Salicylates may raise the level of methotrexate in the serum. Salicylate doses used for cardiovascular event prevention are probably not of concern.

Multivitamins/Fluoride (with ADE)

Magnesium Salts may lower the serum levels of Fluoride and Multivitamins (with ADE). Magnesium salts in particular may lessen the absorption of fluoride. Treatment: Provide magnesium salts at least 1 hour apart from taking a fluoride-containing product to prevent this potential interaction.

Mycophenolate

Magnesium salts may lower the level of mycophenolate in the serum. Treatment: Different doses of mycophenolate and magnesium salts taken orally. If mycophenolate and oral magnesium salts are taken at the same time, watch out for any diminished effects.

Nonsteroidal Anti-Inflammatory Agents (Nonselective)

May intensify salicylates' harmful or hazardous effects. The usage of this combination may raise your risk of bleeding. Salicylates' cardioprotective action may be reduced by nonsteroidal anti-inflammatory drugs (Nonselective). Salicylates may lower the serum level of non-steroidal anti-inflammatory drugs (NSAIDs) (Nonselective).

PenicillAMINE

Products containing polyvalent cations may lower the level of penicillAMINE in the serum. Treatment: Provide oral medications containing polyvalent cations and penicillamine at least an hour apart.

Phosphate Supplements

The serum content of supplements containing phosphate may be lowered by magnesium salts. Management: To reduce the importance of this interaction, administer oral phosphate supplements as far apart as you can from the administration of an oral magnesium salt. Exceptions: Pentahydrate of sodium glycerophosphate.

PRALAtrexate

Salicylates may raise the PRALAtrexate serum concentration. Salicylate dosages used for cardiovascular event prevention are unlikely to cause concern.

Tetracyclines

Tetracyclines may be less readily absorbed when magnesium salts are present. applies only to oral forms of each drug. Eravacycline is an exception.

Trientine

Polyvalent Cation Containing Products may decrease the serum concentration of Trientine. Management: Avoid concomitant administration of trientine and oral products that contain polyvalent cations. If oral iron supplements are required, separate the administration by 2 hours. If other oral polyvalent cations are needed, separate administration by 1 hour.

Vitamin K Antagonists (eg, warfarin)

Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists.

Risk Factor X (Avoid combination)

Baloxavir Marboxil

Polyvalent Cation Containing Products may decrease the serum concentration of Baloxavir Marboxil.

Dexketoprofen

Salicylates may intensify Dexketoprofen's harmful or hazardous effects. Salicylates' potential therapeutic effects may be lessened by dexketoprofen. Salicylates may lower the level of dexketoprofen in the serum. Treatment: Using dexketoprofen with high-dose salicylates (3 g/day or more in adults) is not advised. To reduce any potential interactions, think about giving dexketoprofen 30-120 minutes after or at least 8 hours before cardioprotective doses of aspirin.

Influenza Virus Vaccine (Live/Attenuated)

May intensify salicylates' harmful or hazardous effects. Reye's syndrome in particular could occur.

Raltegravir

Magnesium salts may lower the level of raltegravir in the blood. Avoid using magnesium salts orally or intravenously while taking raltegravir.

Sulfinpyrazone

Sulfinpyrazone's serum levels may be lowered by salicylates.

Varicella Virus-Containing Vaccines

Salicylates may intensify the harmful or hazardous effects of vaccines that contain the varicella virus. In particular, Reye's syndrome risk could rise.